Nathaniel J.Harris (Nate)


(T) 1.202.879.3806 (F) 1.202.626.1700

Nate Harris practices antitrust law, with a focus on litigation, counseling, and defending M&A transactions before antitrust enforcement agencies. He has advised clients on antitrust matters in a variety of industries, including health care, technology, energy, and transportation. He has experience working on matters before the U.S. Department of Justice, the Federal Trade Commission, and various state attorneys general.

Nate's practice encompasses counseling buyers and sellers at various stages of a deal, from premerger planning, through HSR and other regulatory filings, U.S. Department of Justice and Federal Trade Commission investigations, and litigation in federal court. His litigation experience includes drafting motions, fact investigation, deposition preparation, and preparing witnesses for trial. He also has substantial e-discovery experience, including implementing predictive coding and working extensively with document vendors.


  • UPMC prevails in trial before Commonwealth Court of PennsylvaniaJones Day won a bench trial on behalf of the University of Pittsburgh Medical Center ("UPMC"), one of the nation's preeminent integrated healthcare systems.
  • Fortune 500 company resolves DOJ investigation into alleged obstruction of justiceJones Day represented a Fortune 500 company facing investigation by the Department of Justice Antitrust Division for alleged obstruction of justice.
  • Cabell cleared to acquire St. Mary's following dismissal of FTC antitrust lawsuit to block transactionAfter a nearly two-year fight with the U.S. Federal Trade Commission, Cabell Huntington Hospital, Inc. has overcome all regulatory hurdles to its acquisition of St. Mary’s Medical Center, Inc., clearing the way to combine Huntington, West Virginia’s only two health systems.
  • Sanofi defends proposed class action alleging improper Orange Book listings and sham patent litigationJones Day is defending Sanofi-Aventis U.S. LLC against a proposed class action alleging that Sanofi improperly listed certain patents in the FDA's Orange Book and engaged in sham patent litigation to forestall competition for its diabetes drug, Lantus.
  • Parker Hannifin defends $4.3 billion acquisition of CLARCORFollowing a post-closing antitrust investigation, Parker Hannifin Corporation retained Jones Day to act as antitrust counsel in its litigation with the U.S. Department of Justice (DOJ) Antitrust Division over the company’s $4.3 billion acquisition of CLARCOR Inc.
  • CBS Radio merges with EnterCom for $1.6 billionJones Day served as antitrust counsel in the Reverse Morris Trust merger of CBS Corporation subsidiary CBS Radio, Inc. with Entercom Communications Corp.
  • Aetna attempts acquisition of HumanaJones Day represented Aetna Inc. as antitrust counsel in its attempted $37 billion acquisition of fellow health insurer Humana Inc.
  • AREVA sells subsidiary Canberra to Mirion-CharterhouseJones Day represented AREVA in the sale of its subsidiary, Canberra, a leading provider of innovative and cost-effective nuclear instrumentation solutions, to Mirion-Charterhouse.
  • The Carlyle Group secures antitrust clearance for $2.1 billion sale of Landmark Aviation to BBA AviationJones Day represented The Carlyle Group in securing antitrust clearance from the U.S. Department of Justice for its $2.1 billion sale of Landmark Aviation to BBA Aviation plc.
  • Viasystems Group acquired by TTM Technologies for $927 millionJones Day advised Viasystems Group, Inc. in its acquisition by TTM Technologies, Inc. for a combination of cash and stock valued at approximately $368 million, or $16.46 per Viasystems share, based on the TTM closing share price as of September 19, 2014.
  • Exelis acquired by Harris Corporation for $4.8 billionJones Day advised Exelis, Inc. in its acquisition by Harris Corporation in a cash and stock transaction valued at $23.75 per share, or approximately $4.8 billion enterprise value.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.